Go beyond routine care1 More info with
a personalized path for diabetes
prevention2 More info.
Genetic testing can help you learn more about genetic diabetes (T2D) risks that may impact you and your family.
- Includes 7 diabetes-related reports.
- Personalized recommendations.
- Privacy and protection of your data.
Year
Understanding the facts about diabetes.
- It’s not always as obvious as it seems.>1 in 3adults in the US have pre-diabetes but over 80% don’t know it.3 More info
- Early action can lead to a healthier you.40%of the US adult population are expected to develop T2D in their lifetime.4 More info
- Make more informed decisions about your care.80%of diabetes is preventable.5 More info
Why genetic testing matters for diabetes prevention.
![Your genetics are associated with a typical likelihood](/_next/image/?url=%2F_next%2Fstatic%2Fmedia%2Fdiabetes-why-mb.527dc62b.png&w=750&q=75)
- Diabetes is a leading cause of death and disability but it can be prevented.6 More info,7 More info
- Genetics plays a big role in your likelihood of developing T2D and can help you identify hidden risks you may not know about otherwise.
- Unlike routine blood tests that may signal you already have a condition, genetic insights offer you information you can use for early intervention.
Your genetic insights and personalized reports can help you better understand T2D and related conditions.
- Polygenic Risk Scores*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health RisksCombinations of common genetic variants that impact the chances of developing T2D and related conditions.
- Wellness ReportsInsights into how DNA influences your weight.
![A sample Heart Health report. Your genetics are associated with an increased likelihood.](/_next/image/?url=%2F_next%2Fstatic%2Fmedia%2Fdiabetes-report-mb.4ab5b573.png&w=750&q=75)
Genetic information for diabetes conditions and traits.
Also included in your 23andMe+ Premium membership.
- Type 2 Diabetes
- Gestational Diabetes
- High Blood Pressure
- HDL Cholesterol
- Triglyceride
- Nonalcoholic Fatty Liver Disease
- Genetic Weight
- Saturated Fat and Weight
Tools for preventive action and better health over time.
Also included in your 23andMe+ Premium membership.
Health Tracks℠
The Health Tracks feature allows you to better understand how genetics and lifestyle can impact your likelihood of developing type 2 diabetes and certain other conditions over time.
![](/_next/image/?url=%2F_next%2Fstatic%2Fmedia%2Fdb-health-action-plan-mb.8efdfce8.png&w=1920&q=75)
Health Action Plan
Your Health Action Plan allows you to opt in and receive personalized recommendations based on genetic and non-genetic data.
![](/_next/image/?url=%2F_next%2Fstatic%2Fmedia%2Fdb-family-health-tree-mb.58e9ed5c.png&w=1920&q=75)
Family Health History Tree
Opt in to easily input, track and download your family health history to share with your healthcare provider.
Find out what else you can learn from your DNA.
You’ll also receive 190+ reports with new insights and features added throughout the year.
- BRCA1/BRCA2 (Selected Variants) Genetic Health Risk ReportOpt in to view your report results.
- Hereditary Prostate Cancer (HOXB13-Related) Genetic Health Risk ReportOpt in to view your report results.
- MUTYH-Associated Polyposis Genetic Health Risk ReportOpt in to view your report results.
- Breast Cancer (Powered by 23andMe Research) (available for females only)Opt in to view your report results.
- Prostate Cancer (Powered by 23andMe Research) (available for males only)Opt in to view your report results.
- Colorectal Cancer (Powered by 23andMe Research)Opt in to view your report results.
- Skin Cancer (Basal and Squamous Cell Carcinomas) (Powered by 23andMe Research)
- Skin Cancer (Melanoma) (Powered by 23andMe Research)
- Pharmacogenetics Reports
- DPYD Drug Metabolism
- Topic Pages
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Late-Onset Alzheimer’s Disease Genetic Health Risk ReportOpt in to view your report results.
- Related Condition: Parkinson’s Disease Genetic Health Risk Report
- Depression (Powered by 23andMe Research)
- Anxiety (Powered by 23andMe Research)
- Panic Attacks (Powered by 23andMe Research)
- ADHD (Powered by 23andMe Research)
- Sleep Health Matters to Mental Health
- Insomnia (Powered by 23andMe Research)
- Obstructive Sleep Apnea (Powered by 23andMe Research)
- Restless Legs Syndrome (Powered by 23andMe Research)
- Wellness and Trait Reports
- Deep Sleep
- Sleep Movement
- Wake-Up Time
- Familial Hypercholesterolemia Genetic Health Risk Report
- Hereditary Amyloidosis (TTR-Related) Genetic Health Risk Report
- Atrial Fibrillation (Powered by 23andMe Research)
- Coronary Artery Disease (Powered by 23andMe Research)
- High Blood Pressure (Powered by 23andMe Research)
- Type 2 Diabetes (Powered by 23andMe Research)
- LDL Cholesterol (Powered by 23andMe Research)
- HDL Cholesterol (Powered by 23andMe Research)
- Triglycerides (Powered by 23andMe Research)
- Wellness Reports
- Genetic Weight
- Saturated Fat and Weight
- Pharmacogenetics Reports
- SLCO1B1 Drug Transport
- CYP2C19 Drug Metabolism
- Historical MatchesSM feature
- Advanced DNA Relative filters
- Access to up to 5000 DNA relatives
Let’s learn more together.
Add to cartImportant test infoFrequently Asked Questions
- What’s included in 23andMe+ Premium?
- The 23andMeplus Premium is an annual membership and includes everything from our Health plus Ancestry Service plus access to exclusive reports and features that can help you learn more about your heart health, how you process certain medications**Learn about Considerations and Limitations for Pharmacogenetics Reports, likelihood for having migraine, and more. You’ll also receive enhanced ancestry features. Together, these 23andMe reports and features provide a more in-depth dive into your health and ancestry.
- How much does it cost to join 23andMe+ Premium?
- A 23andMeplus Premium membership costs original price: $268 sale price: $199 for new customers (original price: $199 sale price: $130 for kit plus $69 for membership). Existing Ancestry Service customers can upgrade here. Existing Health + Ancestry customers can upgrade here. Membership for new and existing customers renews automatically at $69peryr.
- Can you cancel the 23andMe+ Premium?
- You can cancel your annual 23andMeplus Premium at any time from within your 23andMe Account Settings. Read more about canceling your membership here: https://www.23andme.com/about/tos/subscription/
- Is there a monthly fee for 23andMe?
- We offer two base DNA kits, Ancestry Service and Health plus Ancestry, which are a one-time fee. We also have an optional add-on to the Health plus Ancestry kit, 23andMeplus Premium, which is our annual membership service that offers exclusive access to new premium reports and features throughout the year.
3 Headline: National Diabetes Statistics Report
Link: https://www.cdc.gov/diabetes/php/data-research/?CDC_AAref_Val=https://www.cdc.gov/diabetes/data/statistics-report/index.html
Source: Change to Centers for Disease Control and Prevention
4 Headline: Hispanic or Latino People and Type 2 Diabetes
Link: https://www.cdc.gov/diabetes/communication-resources/hispanic-and-asian-subgroups-are-at-higher-risk-for-diabetes.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/library/features/hispanic-diabetes.html
Source: Change to Centers for Disease Control and Prevention
5 Headline: The preventable proportion of type 2 diabetes by ethnicity: The Multiethnic Cohort
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109209/
Source: National Library of Medicine
6 Headline: About Chronic Diseases
Link: https://www.cdc.gov/chronic-disease/?CDC_AAref_Val=https://www.cdc.gov/chronicdisease/about/index.htm
Source: Center for Disease Control
7 Headline: Prevent Type 2 Diabetes
Link: https://www.cdc.gov/diabetes/prevention-type-2/?CDC_AAref_Val=https://www.cdc.gov/diabetes/prevent-type-2/index.html
Source: Center for Disease Control
*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and PRS reports which are based on a genetic model that includes data and insights from 23andMe consented research participants, and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. Each PRS report describes if a person has a certain likelihood of developing a condition, but does not describe a person’s overall likelihood. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. The MUTYH-Associated Polyposis Genetic Health Risk Report is indicated for reporting the Y179C and G396D variants in the MUTYH gene and an increased risk for colorectal cancer. The two variants included in this report are most common in people of Northern European descent. The Hereditary Prostate Cancer (HOXB13-Related) Genetic Health Risk report is indicated for reporting the G84E variant in the HOXB13 gene. The report describes if a person has the G84E variant and if a male is at increased risk for prostate cancer. The variant included in this report is most common in people of European descent, especially in people of Northern European descent. These reports do not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. These reports are for over-the-counter use by adults, and provide genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. For important information and limitations regarding genetic health risk reports, visit 23andme.com/test-info/.
**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/